NEOGENOMICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.14 USD | +2.09% |
|
+4.51% | -12.61% |
| Apr. 18 | NeoGenomics, Inc. Announces Senior Leadership Promotions | CI |
| Apr. 18 | NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics | CI |
ETFs positioned on NeoGenomics, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.43% | 16 M€ | -8.49% | ||
| 0.97% | 11 M€ | -6.03% | - | |
| 0.29% | 2 M€ | -.--% | ||
| 0.11% | 7 M€ | -.--% | - | |
| 0.07% | 509 M€ | -.--% | ||
| 0.03% | 773 M€ | -.--% | - | |
| 0.02% | 117 M€ | +1.11% | - | |
| 0.02% | 9 M€ | +6.26% | - | |
| 0.01% | 9 M€ | -.--% | - | |
| 0.00% | 147 M€ | +4.88% | - | |
| 0.00% | 8 M€ | +3.41% | - | |
| 0.00% | 18 M€ | +3.41% | - | |
| 0.00% | 33 M€ | +0.25% | - | |
| 0.00% | 18 M€ | +3.86% | - | |
| 0.00% | 34 M€ | +2.14% | - |
NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.
Calendar
2024-04-29
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
14.14
USD
Average target price
21.1
USD
Spread / Average Target
+49.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.61% | 1.81B | |
| -17.89% | 8.25B | |
| +39.20% | 3.57B | |
| -39.11% | 2.46B | |
| -8.06% | 2.46B | |
| -7.35% | 2.38B | |
| -19.01% | 1.55B | |
| -40.66% | 1.21B | |
| +7.56% | 1.11B | |
| -15.34% | 1.03B |
- Stock Market
- Equities
- NEO Stock
- Funds and ETFs NeoGenomics, Inc.
